SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ImmunityBio converts from Immunomedics
IBRX 2.065-2.1%9:49 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Maturin4/30/2025 12:30:27 PM
2 Recommendations

Recommended By
Fitzhughlaw
jargonweary

  Read Replies (1) of 1229
 
This article published a few days ago could explain some of the recent post-equity raise weakness. Given that J&J revealed their phase 2 results at the American Urological Association's annual meeting last weekend it's unlikely that those who recently invested at $3 were aware of the high complete response rate. Management is now focused on the duration of response vs the J&J product but nonetheless, this kind of data must give potential partners reason to pause. Curious on the board's thoughts.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News